This article was originally published in The Gray Sheet
FDA approves Medtronic's Specify 5-6-5 surgical lead for treatment of chronic low back pain with its RestoreAdvanced and PrimeAdvanced neurostimulators, the company announces June 18. Specify 5-6-5 has 16 electrodes in three columns imbedded on a flexible paddle with proprietary DuraLoc technology. The curved shape of the paddle conforms to the epidural space around the spinal cord, allowing consistent contact of the electrodes with the spinal cord's surrounding membrane, Medtronic says...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.